Sandoz targets growth opportunities in respiratory and complex generics

Wed, Mar 16, 2022

  • Sandoz gains significant capabilities and assets in medical and drug device development that target major growth opportunities in respiratory and complex generics
  • Respiratory diseases are leading cause of death and disability and impose huge financial burden on patients worldwide
  • Acquisition further demonstrates Sandoz commitment to pioneer access for patients

Sandoz, a Novartis division, announced today that it has successfully acquired the UK-based medical and drug delivery device development company, Coalesce Product Development Limited.

Through this deal, Sandoz has acquired the significant capabilities and assets of Coalesce, which will help it build on its existing portfolio of respiratory medicines and further improve patient access to these high-quality, complex therapies.

“Respiratory and complex generics are areas of relatively high unmet medical need, due largely to their comparatively high technical complexity,” said Sandoz CEO, Richard Saynor.

“At Sandoz, we have the experience and expertise to succeed in these fields and this acquisition offers us a significant new growth platform, particularly in the US and Europe, reinforcing our commitment to pioneer access for patients.”

Respiratory diseases are leading causes of death and disability worldwide.1 Asthma is a major non-communicable disease affecting both children and adults, and in 2019 it affected an estimated 262 million people.2 In the same year, about 3.23 million deaths were attributed to chronic obstructive pulmonary disease (COPD).3 The resulting burden of respiratory diseases on healthcare systems and productivity amounted to more than USD 380 billion per year across 28 EU member states.4

With an existing portfolio of six in market-products and nearly twice as many more in the pipeline, Sandoz sees respiratory as a key pillar of its ambitious long-term growth strategy and intends to actively explore further opportunities both in-house and externally. More generally, Sandoz is determined to grow its portfolio in the complex generics space, including complex injectables.

 

Article sourced from www.novartis.com/news/
Published: 14.03.22

 

References

  1. Forum of International Respiratory Societies. The Global Impact of Respiratory Disease – Second Edition. Sheffield, European Respiratory Society, 2017.
  2. WHO. Asthma Factsheet. 2021. [Online] Available at: https://www.who.int/news-room/fact-sheets/detail/asthma(Accessed March 2022)
  3. WHO. COPD Factsheet. 2021. [Online] Available at: https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd) (Accessed March 2022)
  4. The European Respiratory Society. The cost of respiratory disease. European Lung white book. Available at: https://www.erswhitebook.org/about/ (Accessed March 2022)



Get in touch

Park Management

Carl Williams
T: +44 (0)1223 347 066

Email Me

Innovation Centre

Miranda Edwards
T: +44 (0)1223 420 252

Email Me

Availability

William Clarke
T: +44 (0)1223 347 294

Email Me